CAJ | 학술논문

目的观察聚乙二醇干扰素α-2a(PEG-IFNa-2a)治疗拉米夫定(LAM)耐药的慢性乙型肝炎(CHB)的疗效和安全性.方法将81例拉米夫定耐药的HBeAg(+)慢性乙型肝炎患者分为聚乙二醇干扰素α-2a(派罗欣)治疗组40例及阿德福韦酯(ADV)对照组41例.两组病例开始均联合LAM治疗12周,观察治疗第12周、24周、48周的ALT复常、HBV DNA阴转、HBeAg阴转及HBeAg转换的变化.结果治疗12周、24周派罗欣治疗组ALT复常率为62.5%、80.0%,高于ADV 对照组,治疗48周派罗欣治疗组HBeAg阴转率及HBeAg转换率为60%、57.5%,高于ADV对照组,差异有统计学意义(P<0.05).结论聚乙二醇干扰素α-2a治疗拉米夫定耐药的HBeAg(+)慢性乙型肝炎的疗效优于阿德福韦酯,安全性较好.
목적 관찰취을이순간우소α-2a(PEG-IFNa-2a)치료랍미부정(LAM)내약적만성을형간염(CHB)적료효화안전성.방법 장81례랍미부정내약적HBeAg(+)만성을형간염환자분위취을이순간우소α-2a(파라흔)치료조40례급아덕복위지(ADV)대조조41례.량조병례개시균연합LAM치료12주,관찰치료제12주、24주、48주적ALT복상、HBV DNA음전、HBeAg음전급HBeAg전환적변화.결과 치료12주、24주파라흔치료조ALT복상솔위62.5%、80.0%,고우ADV 대조조,치료48주파라흔치료조HBeAg음전솔급HBeAg전환솔위60%、57.5%,고우ADV대조조,차이유통계학의의(P<0.05).결론 취을이순간우소α-2a치료랍미부정내약적HBeAg(+)만성을형간염적료효우우아덕복위지,안전성교호.
Objective To observe the efficacy and safety of PEG-interferon α-2a(PEG-IFNα-2a)treatment on lamivudine(LAM)-resistant chronic hepatitis B (CHB)patients.Methods Eighty-one patients with lamivudine-resistant HBeAg (+) chronic hepatitis B patients were enrolled and divided into PEG-IFNα-2a treatment group(40 cases) and adefovir dipivoxil (ADV) control group (41 cases).Two groups were combined with LAM in the first 12 weeks(W).The ALT normalization rate,the HBV DNA and HBeAg negative rate,and the HBeAg seroconversion rate were observed in 12 W,24 W,48 W.Results The ALT normalization rate in 12 W,24 W of PEG-IFNα-2a group was 62.5%and 80.0%.AND it was higher than that of ADV group.The HBeAg negative rate and HBeAg seroconversion rate in 48 W of PEG-IFNα-2a group were 60% and 57.5%,which were higher than that of ADV group.The difference was statistically significant(P<0.05).Conclusion PEG-IFNα-2a treatment of lamivudine-resistant HBeAg (+) chronic hepatitis B is superior to ADV,and its security is well.